Esperion Therapeutics (ESPR) - Cash on Hand per Share

This cash per share chart from GURU.Markets demonstrates the liquidity of Esperion Therapeutics (ESPR), where the parameter has settled at 0.61. This trend is driven by Nexletol sales and partner payments. Stability is supported by eco-standards for drug synthesis and chemical waste control. The company is currently scaling its non-statin portfolio, expanding its presence in the European and US markets.
Comprehensive metric breakdowns and analytics for Esperion Corp (ESPR)

This indicator reflects the liquidity level per common share, allowing for the rapid tracking of capital dilution or write-downs outside of quarterly reports. By analyzing the calculated cash per share, an investor can see the resources Esperion Therapeutics (ESPR) possesses to compete with pharma behemoths for insurance quotas, where a sufficient cash reserve guarantees survival, but an excess may signal stagnation in development.